 There is currently a lack of information regarding the influence of depression on the survival of glioma patients.  Results from six studies were pooled to examine the correlation between depression and survival in patients with low-and high-grade glioma.  Depression was associated with significantly worse survival outcomes, especially among patients with high-grade glioma.  This correlation was not influenced by depression timing (i.e. pre-vs. post-operative).
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Introduction
Presenting symptoms of gliomas not only include seizures, headaches, and neurological dysfunction, but also personality changes and psychiatric disorders such as major depressive disorder (MDD).[1, 2] Such psychiatric abnormalities may have severe consequences in this group of patients. In particular, there is evidence to suggest that the existence of depression in cancer patients predicts cancer incidence, progression, or mortality.
[3] However, the data from glioma patients regarding associations between depression and survival are conflicting; while some studies reported worse survival in glioma patients with preoperative depression, [4] others found no association between depression and survival. [5] Additionally, the retrospective series that explored this association were conducted in different populations, at varying time points, and with various diagnostic tools, making generalizable conclusions nearly impossible. [6] Among the studies that found links between depression and worsened survival outcomes, [7, 8] suggested mechanisms for these deleterious effects were both pathophysiological and behavioral in nature. Biologically, depression may exert various effects A C C E P T E D M A N U S C R I P T 4 on the body's endocrine system, leading to changes that dampen the immune response and indirectly promote tumor growth.
[3] Additionally, depressed individuals may be less likely to seek proper medical treatment, less adherent to traditional treatment regimens,[3] more prone to suicide, [9] and more likely to engage in substance abuse and other high-risk behaviors. [10] Thus, if an association does exist between depression and poorer oncologic outcomes, early identification and intervention for depression in such patients is of utmost clinical importance.
Because of the controversial findings in the depression and survival outcome association in glioma patients, we sought to review the currently available evidence in order to provide potential answers to the following questions in glioma patients: 1) whether there was a significant association between depression and survival among glioma patients; 2) whether these effects were more likely to be observed in certain subgroups of patients, e.g. preoperative vs. postoperative depression assessment, or low-grade vs high-grade gliomas.
Materials and Methods

Search Strategy
This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. [11] We conducted a systematic review of all English articles within the PubMed/MEDLINE, EMBASE and Cochrane databases from the inception of all databases through November 6, 2016 . In order to be as comprehensive in our search as possible, we employed a broad search strategy. Medical subject heading (MeSH) terms included (Brain Neoplasms or Glioma ) AND (Depression or Depressive Disorder, or (Appendix 1). Synonyms and relevant search terms were added according to the pre-specified inclusion/exclusion criteria. All articles from the three databases were exported to Endnote.
Study Selection
Duplicates from the merged database were removed and the remaining articles were evaluated. Existing reviews and references of the most relevant studies were used to supplement the collection of articles, as appropriate. Criteria for inclusion in the meta-analysis were: 1.
Included adult glioma patients (age ≥18 years old); 2. Depression was either clinically diagnosed based on standard diagnostic criteria such as the Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale (HADS), Center for Epidemiologic Studies (CES-D)., or selfrating scales or interviewer ratings; 3. Either survival or mortality information, such as overall survival rate or progression-free survival or mortality was provided; 4. Statistics could be estimated for associations between depression and survival/mortality, such as relative-risk (RR) and confidence intervals (CIs), hazard-ratio (HR) and CIs, survival curves, p values for KaplanMeier analysis or Cox regression. Case reports, as well as reviews, systematic reviews and metaanalyses were excluded, but were utilized for the snowballing process, and for comparison of final results for the discussion. All retrieved articles were evaluated independently by two authors and cross-checked according to their findings. Disagreements, if any, were resolved by a third author.
Data Extraction and quality assessments
A standardized data extraction form was created according to the study objective and research question. The articles selected for the meta-analysis were reviewed and relevant data were extracted independently by two authors. The information extracted included: author, study design, study date, type of publication, follow-up time, study objective, sample size, inclusion
criteria, mean and range of baseline age, source population, depression rating methods, timing of depression assessment, glioma grades, treatment and intervention, definition of survival outcomes, study intervals, reported frequency of depression, and results of study analysis (RR, CI and p-value). For studies on a similar dataset, the most recent reports were included. The quality of the studies was evaluated using the Newcastle-Ottawa scale (NOS), which assesses for three areas, including the selection of the exposed and unexposed participants; the comparability between the groups; and the outcome assessment. [12] NOS scores ranged from 7 to 9, with 9 being the maximum possible score.
Data Analysis
Comprehensive Meta-Analysis (CMA) version 3 (Biostat, Inc., Englewood, NJ, USA) was used for data analysis. Three outcomes were calculated in order to comprehensively investigate the currently available data: 1) binary outcome -the number of survivals and deaths in both depression and non-depression groups separately by the end of the follow-up; 2) continuous outcome -overall survival length in both groups by the end of follow-up; 3) hazard ratio (HR) of death -either originally reported by the paper or calculated from paper if data is available ( Table 1) . A random-effects (RE) model utilizing the DerSimonian-Laird method evaluated within-study variance for comparison. [13] A fixed-effects (FE) model with the inverse variance method was used to obtain the overall relative risk (RR) estimates and the 95 % confidence intervals (95%CI) in order to assess the effect of depression in survival outcomes of glioma patients. Forest plots were utilized for visualization of both individual and summary estimates. Heterogeneity among studies was assessed by using Cochran's Q-statistic (p<0.10) and the I 2 -statistic (>50 % was considered to be high). [14] Heterogeneity was further explored using subgroup analyses for categorical covariates such as glioma grade and depression assessment
time -preoperative or postoperative -for those patients with high grade glioma. A univariate meta-regression was also conducted on study interval (continuous) for patients with high grade tumors. Funnel plots, Egger's linear regression tests, and Begg's correlation tests were used to assess potential publication bias. If any publication bias was indicated, the number of missing studies was evaluated using the trim and fill method. A p-value < 0.05 was considered significant unless otherwise indicated.
Results
Study characteristics
We identified 172 articles from PubMed, 442 articles from Embase, and five articles from Cochrane after a systematic literature search (Fig. 1) . After removal of duplicates and papers that failed to meet the inclusion criteria based on the title and abstract, 53 articles remained for full-text review. Upon completion, 47 articles were excluded as follows: 25 papers did not meet the inclusion criteria; 11 studies were reviews, meta-analyses, commentaries or case reports; one article was excluded (Mainio et al., 2005[8] ) because it was based on the same dataset of a more recent one that was included (Mainio et al., 2006[15] ); seven papers had data that were not extractable; one study which listed progression-free survival (PFS) instead of overall survival (OS); and one study did not focus on gliomas. In the end, six articles were included in our meta-analysis.
Characteristics of the six studies in this meta-analysis are displayed in Table 1 . All six
studies were cohort studies. Three studies were conducted in the USA, two in China and one in Finland. In the depression group, the total number of participants ranged from 6 to 87 and the number of survival cases from 0 to 35; the mean OS ranged from 8 to 69.6 months. In the nondepression group, the total number of participants ranged from 8 to 1003 and the number of survival cases from 0 to 211, the mean for OS ranged from 9 to 140.4 months. Six studies contained information on patients with a high-grade glioma (HGG), while one study provided information on low grade glioma (LGG) patients. The length of study interval also varied across studies from 12 to 168 months. All studies included both male and female patients, but the exact number of each group was not given directly by the studies. Depression was assessed preoperatively in 3 studies-one at baseline during admission, [16] one before the patient was aware of the histologic diagnosis of glioma, [15] and one consisting of a population with a history of depression diagnosed at unspecified periods of time. [4] Depression was assessed postoperatively in 3 studies-one at a mean of 23.5 days after surgery, [17] one every 2 to 3 months up to 12 months, [18] and one immediately during the postoperative period and at 3 and 6 months. [7] It should be noted that while the study by Mainio [15] assessed depression both preoperatively and at 3 and 12 months postoperatively, only the baseline depression assessment was relevant for our analysis. In most of the studies, depression was assessed by the provider, [4, 7, 15, 16, 18] and in only one, depression was also defined by the patients and their relatives. [18] Overall survival outcomes:
Subgroup analyses based on HGG and LGG were performed when investigating both binary ( Fig. 2) and continuous ( Fig. 3) survival outcomes. Forest plots for both binary and continuous survival outcomes showed inverse associations between depression and survival outcomes among glioma patients.
For binary survival outcomes (Fig. 2) No difference was indicated between these groups (P-interaction=0.47; RE; Pinteraction=0.17; FE). Furthermore, the univariate meta-regression on study interval for patients with high grade glioma did not explain the difference in results between the included studies (slope= 0.01, P-interaction=0.43, RE; slope=0.01, P-interaction=0.27, FE), nor did the NOS (slope=0.25, P-interaction=0.77, RE; slope=0.20, P-interaction=0.81, FE).However, subgroup analysis on country revealed a significantly lower survival rate in the studies conducted in the USA (RR=0.05; 95% CI= 0.01; 0.37; 2 studies) than the studies conducted outside the USA (RR=0.83; 95% CI= 0.69; 0.99; 2 studies) (P-interaction<0.01; both RE and FE).
For continuous survival outcomes ( between the included studies (slope=0.1, P-interaction=0.23, RE; slope=0.01, P-interaction=0.06, FE). While the NOS did not explain the difference in results between the included studies under the RE model (slope=-0.17, P-interaction=0.62, RE), it was shown to be statistically significant in the FE model (slope=-0.37, P-interaction<0.01, FE) so that the survival outcomes worsened with higher quality studies.
Among patients with HGG, the pooled HR of death showed a significantly increased risk of death among depressive patients, with a pooled HR of death of 1.42 (95% CI: 1.00, 2.01; RE and FE; 4 studies) and no heterogeneity (I 2 = 0%, P-heterogeneity =0.85) (Fig. 4) . Publication bias was not evaluated due to the paucity of studies. No significant differences comparing
postoperative and preoperative subgroups were found (P-interaction=0.77; RE and FE) not by country (P-interaction=0.60 RE and FE). Furthermore, a subgroup analysis based on the types of HR -directly reported from the article vs. calculated from article -displayed no statistically significant difference between these two groups (P-interaction=0.49; RE and FE). Univariate meta-regression on NOS did not explain the difference in results between the included studies (slope=0.13, P-interaction=0.61, RE and FE); while that on study interval could not be evaluated because only three studies out of four reported it.
Discussion
The present study demonstrated statistically significantly worse survival outcomes among glioma patients with depression versus those without depression. Among high-grade glioma patients, in particular, a positive association between depression and death was detected. shorter survival times in low-grade glioma patients with depression as compared to those without depression. [8] The results of these retrospective series are consistent with the overall poorer survival outcomes that we reported in our meta-analysis.
Previous studies have found specific associations between time of depression diagnosis and overall survival. One study found that preoperative depression was independently associated
with decreased survival in malignant astrocytoma patients, independent of degree of disability, WHO Grade III vs. IV, and subsequent treatment. [4] Another study demonstrated that depression was more common immediately after surgery for gliomas, and found that postoperative depression was associated with shorter survival times and a greater rate of complications. [7] While our meta-analysis found increased rates of depression and poorer overall survival in both pre-and postoperative groups, per the FE model, the association between depression and worse survival was stronger in the group diagnosed preoperatively.
Some prior studies have reported worse survival in depressed patients with high grade gliomas. [16, 18] In contrast, another study demonstrated shorter survival times in depressed patients with low-grade gliomas as compared to non-depressed patients with low-grade gliomas.
In this same study, no such relationship was found when comparing depressed and nondepressed patients with high-grade or benign brain tumors. [8] A retrospective study published in 2009 found that preoperative depression was associated with decreased survival of brain tumor patients independent of tumor grade. [4] When conducting sub-group analyses by tumor grade, our meta-analysis did not detect a statistically significant difference in survival outcomes when comparing both grades. We likely need additional studies to increase the power of detecting such a difference, as has been reported in other studies.
Various theories surrounding the pathophysiology for depression in cancer patients have been proposed. One possibility is that cancer leads to dysregulation of the hypothalamicpituitary-adrenal axis and subsequently to changes in cytokine levels in the brain. 
Limitations and strengths
One limitation of this meta-analysis was the different assessment tools for depression and the different time points for screening depression among the six studies included. [4, 7, 8, [16] [17] [18] [19] All of the included studies were conducted at different institutions with the different treatment strategies and follow-up protocols. Nevertheless, we investigated potential sources of heterogeneity through meta-regression on continuous variables (study interval, study quality) or subgroup analyses on categorical variables (country of origin, depression assessment timing).
Additionally, we used a standardized mean difference for continuous outcomes. Because treatment information for depression was not available, we were unable to account for the effects of such treatments in our analysis. More generally, we acknowledge that survival does not only depend on depression, but on many other patient-and tumor-related characteristics. Given the lack of reporting of several variables by some studies, it was not possible to control for variables such as tumor genetics or any interval treatment for depression.
Despite these limitations, this meta-analysis based on cohort studies evaluated several different outcomes after extensive review of the literature. To our knowledge, this is the first meta-analysis on this topic. The use of both random-and fixed-effects models together with different subgroup and meta-regression analyses resulted in critical evaluation of our outcomes.
Furthermore, a statistically significant relationship between depression in brain tumor patients and poorer survival outcomes was identified. Last, funnel plots as well as the Begg's rank correlation tests were conducted to identify any potential publication bias and no statistically significant publication bias was found, when such analysis was feasible.
Conclusions
This meta-analysis suggested that high grade glioma patients with depression experienced lower rates of survival as compared to their non-depressed counterparts, as measured by number of survivors, overall survival duration, and HR of death. Given the widespread prevalence of depression in cancer patients and its implication on patient outcomes, our study highlights the need for physicians to evaluate all glioma patients, especially the high-grade glioma, for depression before and after treatment. Future studies should focus on determining the impact of early detection and treatment of depression on outcomes of glioma patients.
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Appendix A. 
Cochrane
Results= 5
AB depressive OR TI depressive OR AB depression* OR TI depression* OR AB melancholia* OR TI melancholia* OR AB melancholy OR TI melancholy OR AB melancholic OR TI melancholic OR AB depressed mood* OR TI depressed mood* OR AB dysthymic disorder* OR TI dysthymic disorder* OR AB adjustment disorder* OR TI adjustment disorder* OR AB adjustment reaction* OR TI adjustment reaction* OR AB transient situational disorder* OR TI transient situational disorder* OR AB Reactive Disorder* OR TI Reactive Disorder* OR AB Anniversary Reaction* OR TI Anniversary Reaction* OR AB mood disorder* OR TI mood disorder* OR AB seasonal affective disorder* OR TI seasonal affective disorder* OR AB bipolar disorder* OR TI bipolar disorder* OR AB premenstrual dysphoric disorder* OR TI premenstrual dysphoric disorder* OR AB pseudodementia OR TI pseudodementia OR AB dysphoria OR TI dysphoria OR AB dysthymia OR TI dysthymia OR AB mourning syndrome* OR TI mourning syndrome* OR AB Perry syndrome*OR TI Perry syndrome* AND AB survival* OR TI survival* OR AB survivorship OR TI survivorship OR AB fatality OR TI fatality OR AB fatalities OR TI fatalities OR AB fatal case* OR TI fatal case* OR AB fatal outcome* OR TI fatal outcome* OR AB disease free survival* OR TI disease free survival* OR AB disease-free survival* OR TI disease-free survival* OR AB event free survival* OR TI event free survival* OR AB event free OR TI event free OR AB event-free survival* OR TI event-free survival* OR AB progression free survival* OR TI progression free survival* OR AB progression free OR TI progression free OR AB progression-free survival* OR TI progression-free survival* OR AB mortality OR TI mortality OR AB mortalities OR TI mortalities OR AB Case Fatality Rate Efficacy funnel plot of standard difference in overall survival means according to their standard errors utilizing both the fixed-effect model (right) and random-effect model (left). The vertical solid line is drawn at the pooled standard difference in means, and the other two lines represent the expected 95% confidence interval for a given standard error. The plot shows no significant publication bias. The trim and fill method shows that the recalculated pooled risk estimate is identical to the original risk estimate. 
Fig. 2
Forest plot represents the relative risk for survival outcomes (95 % CI) for brain tumor patients with depression compared to without depression, grouped by two cancer grades: low and high. Horizontal lines denote 95 % CIs, solid squares represent the point estimate of each study and the diamond represents the pooled estimate of the intervention effect. High cancer grade subgroup: I 2 = 54.9%, P-heterogeneity =0.05, 6 studies; Low cancer grade subgroup: I 2 = 0%, Pheterogeneity =1.00, 1 study. P-interaction comparing high to low=0.37 (RE) or 0.26 (FE). Duplicates removed n=54
Articles excluded n = 512 (either non-relevant or non-English)
Full-text articles assessed for eligibility n = 53
Studies included in quantitative synthesis (meta-analysis) n = 6
Studies excluded n = 47:  Studies failed to meet inclusion criteria excluded n = 25  Studies (reviews, metaanalyses, commentaries, case reports) for further reference n =11  Based on the same dataset n=2  Data not extractable n=7  PFS, not OS n=1  Non-glioma n=1 
Model Study name
Hazard ratio and 95% CI 
